FDA-cleared profile

DS Core Detect

Dentsply Sirona, Inc. · CBCT · FDA-cleared (510(k))

Authorized purpose: Concurrent-read incidental detection of permanent teeth that may be associated with periapical radiolucencies in CBCT data acquired for other reasons.

Clinical role
Concurrent-read incidental PARL detection support with user confirmation or rejection of flagged teeth
Images and patients
CBCT · Permanent teeth and periapical dental structures
Key limitation
Keep in mind: Incidental use only on already-acquired CBCT; not a replacement for complete dentist review or clinical judgment and not an indication to obtain X-ray images. The FDA population is adults aged 22 years or older with permanent teeth.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Concurrent-read incidental detection of permanent teeth that may be associated with periapical radiolucencies in CBCT data acquired for other reasons.
  • Which images or clinical context are in scope?Modality: CBCT Anatomy or clinical context: Permanent teeth and periapical dental structures Input: Existing CBCT data from adult patients aged 22 years or older with permanent teeth; the data must already have been acquired for other reasons and is viewed through the dental image viewer.
  • Who uses it?Intended users: Trained and licensed dentists
  • What does the software produce?Output: A list of teeth that may potentially have periapical radiolucency and a corresponding PARL map; the dentist can confirm or reject each flagged tooth. Two operating points are available: Standard sensitivity and High sensitivity.
  • What is its most important limitation?Key limitation: Incidental use only on already-acquired CBCT; not a replacement for complete dentist review or clinical judgment and not an indication to obtain X-ray images. The FDA population is adults aged 22 years or older with permanent teeth.

Clinical takeaway. Clinical role: Concurrent-read incidental detection of permanent teeth that may be associated with periapical radiolucencies in CBCT data acquired for other reasons.

Evidence takeaway. Evidence from the reviewed source record: FDA testing included standalone and fully crossed MRMC studies. The representative standalone study used 306 CBCTs; high-sensitivity operating-point results were sensitivity 0.78 (95% CI 0.74-0.81) and specificity 0.93 (0.92-0.94), while standard-sensitivity results were 0.66 (0.62-0.70) and 0.97 (0.97-0.98). The MRMC study used 11 US readers and reports unaided/aided model-based AUC 0.415/0.639, tooth-level sensitivity 0.421/0.649, and specificity 0.962/0.946. The FDA ground truth was a consensus reference for the standalone study and reader performance was evaluated separately.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Concurrent-read incidental detection of permanent teeth that may be associated with periapical radiolucencies in CBCT data acquired for other reasons.
  • Exact FDA submission
  • Checked 2026-09-08
Workflow role
Concurrent-read incidental PARL detection support with user confirmation or rejection of flagged teeth
  • Exact FDA submission
  • Checked 2026-09-08
Required input
Existing CBCT data from adult patients aged 22 years or older with permanent teeth; the data must already have been acquired for other reasons and is viewed through the dental image viewer.
  • Exact FDA submission
  • Checked 2026-09-08
Output and clinician action
A list of teeth that may potentially have periapical radiolucency and a corresponding PARL map; the dentist can confirm or reject each flagged tooth. Two operating points are available: Standard sensitivity and High sensitivity.
  • Exact FDA submission
  • Checked 2026-09-08
Care setting
Dental clinical workflow through a dental image viewer; adult patients aged 22 years or older with permanent teeth
  • Exact FDA submission
  • Checked 2026-09-08
Intended users
Trained and licensed dentists
  • Exact FDA submission
  • Checked 2026-09-08
Limitations
Incidental use only on already-acquired CBCT; not a replacement for complete dentist review or clinical judgment and not an indication to obtain X-ray images. The FDA population is adults aged 22 years or older with permanent teeth.
  • Exact FDA submission
  • Checked 2026-09-08
Evidence summary
FDA testing included standalone and fully crossed MRMC studies. The representative standalone study used 306 CBCTs; high-sensitivity operating-point results were sensitivity 0.78 (95% CI 0.74-0.81) and specificity 0.93 (0.92-0.94), while standard-sensitivity results were 0.66 (0.62-0.70) and 0.97 (0.97-0.98). The MRMC study used 11 US readers and reports unaided/aided model-based AUC 0.415/0.639, tooth-level sensitivity 0.421/0.649, and specificity 0.962/0.946. The FDA ground truth was a consensus reference for the standalone study and reader performance was evaluated separately.
  • Exact FDA submission
  • Checked 2026-09-08

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA testing included standalone and fully crossed MRMC studies. The representative standalone study used 306 CBCTs; high-sensitivity operating-point results were sensitivity 0.78 (95% CI 0.74-0.81) and specificity 0.93 (0.92-0.94), while standard-sensitivity results were 0.66 (0.62-0.70) and 0.97 (0.97-0.98). The MRMC study used 11 US readers and reports unaided/aided model-based AUC 0.415/0.639, tooth-level sensitivity 0.421/0.649, and specificity 0.962/0.946. The FDA ground truth was a consensus reference for the standalone study and reader performance was evaluated separately.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Reported sensitivity
78% (95% CI: 74%, 81%)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model sensitivity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

Reported specificity
93% (95% CI: 92%, 94%)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model specificity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

DS Core Detect regulatory performance study summary

  • DesignStand-alone performance and reader study (ACR AI Central category)
  • PopulationAdult
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K253009
  • IndependenceIndependence not established

K253009

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K253009. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-08
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Existing CBCT data from adult patients aged 22 years or older with permanent teeth; the data must already have been acquired for other reasons and is viewed through the dental image viewer.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-08 · FDA K253009: DS Core Detect

  2. Routing

    Source context, not route validation: Cloud-based SaMD accessed by a dental practitioner through a dental image viewer, where CBCT images and device results are viewed together. The FDA packet does not specify PACS, RIS, EHR, or DICOM interface details.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-08 · FDA K253009: DS Core Detect

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-08 ·

  4. Returned objects

    Source context, not route validation: A list of teeth that may potentially have periapical radiolucency and a corresponding PARL map; the dentist can confirm or reject each flagged tooth. Two operating points are available: Standard sensitivity and High sensitivity.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-08 · FDA K253009: DS Core Detect

  5. Viewer/worklist/report

    Unresolved route: A list of teeth that may potentially have periapical radiolucency and a corresponding PARL map; the dentist can confirm or reject each flagged tooth. Two operating points are available: Standard sensitivity and High sensitivity.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-08 · FDA K253009: DS Core Detect

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
Cloud-based SaMD accessed by a dental practitioner through a dental image viewer, where CBCT images and device results are viewed together. The FDA packet does not specify PACS, RIS, EHR, or DICOM interface details.
  • Exact FDA submission
  • Checked 2026-09-08

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for DS Core Detect; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-08
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K253009
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CBCT
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Anatomy
Permanent teeth and periapical dental structures
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2026-01-07
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
23Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, acr ai central product, fda decision summary, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission

    No public price or quote for the exact K253009 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Deployment: Not verified - checked 2026-09-08 - Exact FDA submission

    The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-08 - Exact FDA submission

    Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-08 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

7 sources - 3 history items

Source ledger

  1. FDA K253009: DS Core Detect

    U.S. Food and Drug Administration - Published 2026-01-07 - Accessed 2026-09-08

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. DS Core Detect model card (K253009)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, limitations, reportedSensitivity, reportedSpecificity, evidenceSummary, anatomy, evidenceStudies

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K253009

    U.S. Food and Drug Administration - Accessed 2026-09-08

    Scope: postmarketSafety

Research history

  1. K253009 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K252934

Diagnocat

DGNCT, LLC

Authorized purpose: Diagnocat is an automated concurrent-read aid for detecting periapical radiolucency on permanent teeth in previously acquired, clinically justified maxillofacial CBCT; it is a second-read aid and does not replace complete dental-professional review or judgment.

Modality
CBCT
Anatomy
Maxillofacial region; permanent teeth; periapical radiolucency
Decision
2026-01-15
FDA-cleared K260785

DS Core CBCT Anatomy

Dentsply Sirona

Authorized purpose: DS Core CBCT Anatomy uses CBCT and digital-impression data to provide tooth and jaw segmentation, inferior-alveolar-nerve-canal segmentation, panoramic-curve support, and registration for dental professionals.

Modality
CBCT
Anatomy
Teeth; jaws; and the inferior alveolar nerve canal
Decision
2026-04-23
FDA-cleared K252538

CEPHX3D

Orca Dental AI, Ltd.

Authorized purpose: CEPHX3D processes dental and craniomaxillofacial images to support diagnosis and treatment planning, including three-dimensional models, viewing, segmentation, measurements, and dental-solution design input for patients age 12 and older.

Modality
CBCT
Anatomy
Dental and craniomaxillofacial anatomy
Decision
2026-03-05
FDA-cleared K251514

Overjet CBCT Assist

Overjet, Inc.

Authorized purpose: Dental and craniomaxillofacial CBCT segmentation, measurement and visualization support

Modality
CBCT
Anatomy
Dental/Maxillofacial
Decision
2025-12-05

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history